LXRX - Lexicon Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$6.00
DETAILS
HIGH:
$6.00
LOW:
$6.00
MEDIAN:
$6.00
CONSENSUS:
$6.00
UPSIDE:
177.78%
About Lexicon Pharmaceuticals, Inc. (https://www.lexpharma.com)
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael Exton | Chief Executive Officer & Director | 1970 | $1,149,418 USD |
| Craig Granowitz | Senior Vice President & Chief Medical Officer | 1965 | $789,535 USD |
| Brian T. Crum | Senior Vice President, General Counsel & Secretary | 1973 | $687,366 USD |
| Scott Coiante | Senior Vice President & Chief Financial Officer | 1967 | $646,287 USD |
| Wendy E. McDermott | Senior Vice President of Human Resources | 1971 | $580,446 USD |
| Kristen L. Alexander | Vice President of Finance & Accounting | 1968 | $379,807 USD |
| Lisa DeFrancesco | Senior Vice President of Investor Relations & Corporate Communications | 1980 | – |
| Rachel Yap Martens | Senior VP of Partnerships & Corporate Strategy | 1984 | – |
| Suma Gopinathan | Senior Vice President of Discovery | 1973 | – |